Reporter Shin Chang-min, Biospectator
This article is ‘Premium News Service BioS+’ Article.
EBV-infected multiple sclerosis phase 2 interim analysis does not predict symptom improvement…IDSMC recommends proceeding until primary endpoint evaluation is complete
Interim analysis questioning the efficacy of Atara Biotherapeutics’ Phase 2 clinical trial of ‘ATA188’, a candidate for multiple sclerosis (MS) T-cell treatment with Abstein-Barr virus (EBV) infection ) gave the results.
Six months following ATA188 administration, the independent Data Safety Monitoring Committee (IDSMC) gave an opinion that it was impossible to determine whether the primary endpoint was achieved as a result of the efficacy evaluation. The primary endpoint of clinical trials is whether MS symptoms improve following 12 months of administration. The IDSMC recommends that Atara continue the trial until it can complete the primary endpoint evaluation without further recruitment.
Atara did not disclose specific data.
Atara announced the results of this interim analysis on the 12th (local time) of the ATA188 Phase 2 clinical trial. Atara shares on the Nasdaq market have fallen 55.08% since the news broke…
Additional content is only available to paid members.
If you are a member login If you would like to become a member, please click Please.
